OnCARlytics by Imugene for Solid Tumor: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OnCARlytics overview

onCARlytics (CF33-CD19) is under development for the treatment of solid tumors such as triple-negative breast cancer and hepatocellular carcinoma. The drug candidate comprises of T-cells genetically engineered to express chimeric antigen receptors (CAR-T) delivered through CF33 oncolytic virus targeting cells expressing CD19. It is administered through intravenously and intratumorally.

Imugene overview

Imugene is a clinical-stage biopharmaceutical company that focuses on the development of vaccines in the area of oncology. The company develops immunotherapies that activate the immune system of cancer patients to identify and eradicate tumors. The company develops products for the treatment of various tumors including gastric, breast, lung cancers. Imugene’s lead product candidate, CF33 is a chimeric vaccinia poxvirus for the treatment of mixed advanced solid tumors (MAST) and metastatic triple-negative breast cancer. It develops vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes recognized by an antibody with antitumor activity. Imugene is headquartered in Sydney, New South Wales Australia.

For a complete picture of OnCARlytics’s drug-specific PTSR and LoA scores, buy the report here.

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.